



HHS Public Access

Author manuscript

Clin Cancer Res. Author manuscript; available in PMC 2016 September 01.

Published in final edited form as:

Clin Cancer Res. 2015 September 1; 21(17): 3888–3895. doi:10.1158/1078-0432.CCR-14-2751.

Superiority of [⁶⁸Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of *SDHB*-associated metastatic pheochromocytoma and paraganglioma

Ingo Janssen^{1,9}, Elise M. Blanchet², Karen Adams¹, Clara C. Chen³, Corina M. Millo⁴, Peter Herscovitch⁴, David Taieb⁵, Electron Kebebew⁶, Hendrik Lehnert⁷, Antonio T. Fojo⁸, and Karel Pacak¹

¹Program in Adult and Reproductive Endocrinology, *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, National Institutes of Health, 10 Center Dr., Bldg. 10, Room 1E-3140, Bethesda, MD, 20892

²Nuclear Medicine Department, Bichat Hospital, 46 Rue Henri Huchard, 75018 Paris, France

³Nuclear Medicine Division, Radiology & Imaging Sciences, National Institutes of Health Clinical Center, 10 Center Dr., Bldg. 10, Room 1C-459, Bethesda, MD, 20892

⁴Positron Emission Tomography Department, National Institutes of Health Clinical Center, National Institutes of Health, 10 Center Dr., Bldg. 10, Rooms 1C-401 and 490, Bethesda, MD, 20892

⁵Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France

⁶Endocrine Oncology Branch, National Cancer Institute, 10 Center Dr., Bldg. 10, Room 4-5952, Bethesda, MD, 20892

⁷Department of Internal Medicine I, University Hospital Schleswig Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany

⁸Center for Cancer Research, National Cancer Institute, 10 Center Dr., Bldg. 10, Room 12C-103, Bethesda, MD, 20892

⁹Department of Radiology and Nuclear Medicine, Section of Nuclear Medicine, University Hospital Schleswig Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany

Abstract

Purpose—Patients with succinate dehydrogenase subunit *B* (*SDHB*) mutation-related pheochromocytoma/paraganglioma (PHEO/PGL) are at a higher risk for metastatic disease than other hereditary PHEOs/PGLs. Current therapeutic approaches are limited but the best outcomes are based on the early and proper detection of as many lesions as possible. Because PHEOs/PGLs

Corresponding author: Karel Pacak, MD, PhD, DSc, Senior Investigator, Chief, Section on Medical Neuroendocrinology, Professor of Medicine, *Eunice Kennedy Shriver* NICHD, NIH, Building 10, CRC, Room 1E-3140, 10 Center Drive MSC-1109, Bethesda, MD, 20892, Phone: (301) 402-4594, Fax: (301) 402-4712, karel@mail.nih.gov.

Conflict of interest: The authors claim no conflicts of interest.

overexpress somatostatin receptor 2 (SSTR2), the goal of our study was to assess the clinical utility of [⁶⁸Ga]-DOTA(0)-Tyr(3)-octreotate ([⁶⁸Ga]-DOTATATE) positron emission tomography/computed tomography (PET/CT) and to evaluate its diagnostic utility in comparison to the currently recommended functional imaging modalities [¹⁸F]-fluorodopamine ([¹⁸F]-FDA), [¹⁸F]-fluorodihydroxyphenylalanine ([¹⁸F]-FDOPA), [¹⁸F]-fluoro-2-deoxy-D-glucose ([¹⁸F]-FDG) PET/CT as well as CT/magnetic resonance imaging (MRI).

Experimental Design—[⁶⁸Ga]-DOTATATE PET/CT was prospectively performed in 17 patients with *SDHB*-related metastatic PHEOs/PGLs. All patients also underwent [¹⁸F]-FDG PET/CT and CT/MRI with 16 of the 17 patients also receiving [¹⁸F]-FDOPA and [¹⁸F]-FDA PET/CT scans. Detection rates of metastatic lesions were compared between all these functional imaging studies. A composite synthesis of all used functional and anatomical imaging studies served as the imaging comparator.

Results—[⁶⁸Ga]-DOTATATE PET/CT demonstrated a lesion-based detection rate of 98.6% (95% confidence interval (CI) 96.5% to 99.5%), [¹⁸F]-FDG, [¹⁸F]-FDOPA, [¹⁸F]-FDA PET/CT, and CT/MRI showed detection rates of 85.8% (CI 81.3% to 89.4%) (p<0.01), 61.4% (CI 55.6% to 66.9%) (p<0.01), 51.9% (CI 46.1% to 57.7%) (p<0.01), and 84.8% (CI 80.0% to 88.5%) (p<0.01), respectively.

Conclusions—[⁶⁸Ga]-DOTATATE PET/CT showed a significantly superior detection rate compared to all other functional and anatomical imaging modalities and may represent the preferred future imaging modality in the evaluation of *SDHB*-related metastatic PHEO/PGL.

Keywords

[⁶⁸Ga]-DOTATATE; [¹⁸F]-fluoro-2-deoxy-D-glucose; pheochromocytoma; paraganglioma; metastatic

INTRODUCTION

Pheochromocytomas/paragangliomas (PHEOs/PGLs) are tumors derived from sympathetic tissue in adrenal or extra-adrenal abdominal locations or from parasympathetic tissue in the thorax or head and neck (1). More than 35% of PHEOs/PGLs are hereditary, including multiple endocrine neoplasia 2 (MEN2), von Hippel-Lindau syndrome (VHL), and neurofibromatosis 1 (NF1). In recent years, gene mutations encoding the 4 subunits of the succinate dehydrogenase (*SDH*) complex (2, 3), fumarate hydratase (*FH*) (4), MYC-associated factor X (*MAX*) (5), and hypoxia-inducible factor 2 α (*HIF2A*) (6) have been evaluated and often found to be associated with the presence of multiple and metastatic PHEOs/PGLs.

More than 40% of metastatic PHEOs/PGLs are related to succinate dehydrogenase subunit *B* (*SDHB*) mutation carriers (7), who are at high risk for developing metastatic disease. Some studies show a risk of up to 90% (8), with an only 36% 5-year probability of survival after diagnosis of metastatic disease (7). Proper staging and early detection of metastatic disease and evaluation of the extent of metastatic disease in these high risk patients is crucial and has a major effect on a patient's prognosis, including choosing the necessary treatment and follow-up (9).

Current treatment options in metastatic PHEOs/PGLs are limited and consist of radionuclide therapy with [¹³¹I]-metaiodobenzylguanidine (MIBG) and chemotherapy with cyclophosphamide, vincristine, and dacarbazine (CVD) (10, 11). Surgery and external beam radiotherapy are less commonly used options in some patients. However, at least 50% of patients with metastatic PHEOs/PGLs, especially those with *SDHB* mutations, do not benefit from [¹³¹I]-MIBG treatment due to a lack of the norepinephrine transporter system, resulting in suboptimal or no [¹³¹I]-MIBG-uptake (12). The use of CVD is a good alternative, but is reserved for patients with rapidly growing tumors or extensive organ tumor burden (especially in the liver) and limited by treatment-related toxicity. Thus, there is great interest and need to find new means of therapeutic options, including radionuclide therapy.

PHEOs/PGLs, similar to other neuroendocrine tumors (NETs), are known to express somatostatin receptors (SSTRs) (13) and new, promising radiolabelled DOTA-peptides for SSTR imaging and SSTR-targeting treatment have been developed.

Compared to [¹¹¹In]-DTPA-octreotide (Octreoscan), which is used for SSTR scintigraphy, the newly developed DOTA-peptides such as DOTA(0)-Tyr(3)-octreotate (DOTATATE), DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC), and DOTA(1)-Nal(3)-octreotide (DOTANOC) bind to SSTR expressing tumors much more effectively (14). In particular, DOTATATE has a very high affinity for SSTR2, (14), which is overexpressed in most PHEOs/PGLs (13), and has recently been used for their localization (15). Increased expression of SSTR2A and SSTR3 was recently shown in PHEOs/PGLs with *SDH* deficiency (16), including *SDHB* mutations.

DOTA-peptides can either be labeled with the diagnostic positron emission tomography (PET) tracer [⁶⁸Ga] or therapeutic β -emitters like [¹⁷⁷Lu] or [⁹⁰Y]. On one hand, they can provide sensitive SSTR-imaging, enabling improved anatomic localization using PET/computed tomography (CT) technique (17) compared to SSTR scintigraphy. On the other hand, when bound to therapeutic β -emitters, they can and are used for peptide receptor radionuclide therapy (PRRT) in SSTR overexpressing tumors, especially gastroenteropancreatic NETs (18). Treatment results in metastatic PHEOs/PGLs are also promising (19).

The present study had two main aims: first, to evaluate [⁶⁸Ga]-DOTATATE PET/CT in patients with metastatic *SDHB*-related PHEOs/PGLs and assess their eligibility for future PRRT as a new and needed therapeutic approach; and second, to assess the diagnostic value of [⁶⁸Ga]-DOTATATE PET/CT in comparison to other well-established and currently recommended functional imaging studies in PHEOs/PGLs (20), including [¹⁸F]-fluorodopamine ([¹⁸F]-FDA), [¹⁸F]-fluorodihydroxyphenylalanine ([¹⁸F]-FDOPA), [¹⁸F]-fluoro-2-deoxy-D-glucose ([¹⁸F]-FDG) PET/CT, and in comparison to CT/magnetic resonance imaging (MRI). Because histological proof was not possible in many metastatic lesions, the composite of both anatomical and all functional imaging tests was considered the imaging comparator.

PATIENTS AND METHODS

Patients

Between January and December 2014, 17 consecutive patients (11 men, 6 women) with *SDHB* mutation-associated PHEOs/PGLs with a mean age of 40.3 ± 14.0 years were prospectively evaluated at the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) at the National Institutes of Health (NIH). All patients had proven metastatic PHEOs/PGLs based on clinical evaluation, including previously found and surgically removed PHEOs/PGLs, biochemical diagnosis, and anatomical and functional imaging.

The study protocol was approved by the institutional review board of the *Eunice Kennedy Shriver* NICHD (protocol: 00-CH-0093). All patients provided written informed consent for all clinical, genetic, biochemical, and imaging studies regarding PHEOs/PGLs.

Mean age at diagnosis of primary PHEO/PGL in these patients was 30.2 ± 15.0 years. The average interval between diagnosis of a primary tumor and referral to the NIH was 4.5 ± 3.8 years. All 17 patients previously underwent resection of their primary PHEO/PGL. Individual patient characteristics are summarized in Table 1.

Imaging Techniques

CT scans of the neck, chest, abdomen, and pelvis were performed using the following devices: Siemens Somatom Definition AS, Siemens Somatom Definition Flash, Siemens Medical Solutions; Toshiba Aquilion ONE, Toshiba Medical Systems. Section thickness was up to 3 millimeters (mm) in the neck and 5 mm through the chest, abdomen, and pelvis. All studies were performed with intravenous (i.v.) rapid infusion of nonionic water-soluble contrast agent as well as oral contrast material.

MR scans of the neck, chest, abdomen, and pelvis were obtained with 1.5 and 3 Tesla scanners (Philips Achieva 1.5 and 3 Tesla, Philips Medical Systems; Siemens Verio 1.5 Tesla, Siemens Medical Solutions). Image thickness was 5 mm for all neck studies and 6 mm for chest, abdominal, and pelvic scans. Pre- and post-injection images were obtained in the axial plane. All MR scans included axial T2 series with and without fat saturation, STIR series, and T1 pre- and post-contrast series. MR scans of the abdomen and pelvis also included axial T1 in and out of phase and dynamic THRIVE during infusion of contrast, followed by delayed axial and coronal post-contrast scans after i.v. injection of a gadolinium-diethylenetriamine pentaacetic acid contrast agent.

All 17 patients underwent [^{68}Ga]-DOTATATE, [^{18}F]-FDG PET/CT scanning, and CT/MRI, with 16 also receiving [^{18}F]-FDOPA and [^{18}F]-FDA PET/CT scans.

PET/CT scans from the upper thighs to the skull were performed 60 min after i.v. injection of a mean administered activity of 201.8 ± 39.6 MBq [^{68}Ga]-DOTATATE, 60 min after 362.8 ± 112 MBq [^{18}F]-FDG, 30 min after 458.5 ± 83.1 MBq [^{18}F]-FDOPA, and approximately 8 min after 37.2 ± 1.1 MBq [^{18}F]-FDA. 60 min before each [^{18}F]-FDOPA scan, 200 milligrams (mg) of carbidopa were administered orally. All PET/CT scans were

performed on a Siemens Biograph-mCT 128 PET/CT scanner (Siemens Medical Solutions). PET imaging was obtained in 3D mode. PET images were reconstructed on a 256×256 matrix using an iterative algorithm provided by the manufacturer, which also uses time of flight (TOF). Low-dose CT studies for attenuation correction and anatomic co-registration were performed without contrast and used for anatomical localization only.

Analysis of Data

[^{68}Ga]-DOTATATE PET/CT studies were each read independently by two nuclear medicine physicians blinded to all imaging and clinical data except for the diagnosis, sex, and age of the patient.

Maximal standardized uptake values (SUV_{max}) were determined and focal areas of abnormal uptake showing a higher SUV_{max} than surrounding tissue were considered as lesions. Discrepancies, which occurred in 6 lesions with a mean SUV of 6.2 ± 5.6 in 4 patients, were solved by consensus review. In all other imaging studies, physicians were blinded to [^{68}Ga]-DOTATATE PET/CT scans and clinical data except for diagnosis, sex, age of the patient, and previous imaging studies. All imaging studies were performed within 22 ± 15 days of each other. For regional analysis, adrenal glands, liver, abdominal/pelvic compartments (excluding adrenal glands and liver), lungs, mediastinum, and bone were analyzed separately. A patient or region was considered positive regardless of the number of positive findings. Patient-to-patient, region-to-region, and lesion-to-lesion analyses were performed. If the number of lesions in a region exceeded 15, the count was truncated at 15. Patient-, region-, and lesion-related detection rates were compared. Head and neck PGLs were excluded from the analysis in patients with head and neck PGLs and sympathetic PGLs.

Histologic proof of metastatic lesions was not feasible. The composite of anatomic and all performed functional imaging tests was considered the imaging comparator. A positive result on at least two different functional imaging modalities or at least one functional imaging study and CT/MRI was counted as true disease, whereas a lesion detected only on CT/MRI or only on one functional imaging test while negative on all other used imaging tests was considered a false-positive imaging result.

Statistics

Results are given as means with 95% confidence intervals (CIs) unless stated otherwise. For statistical analysis, the McNemar test was used to compare sensitivities between [^{68}Ga]-DOTATATE PET/CT and the other imaging modalities. A two-sided $p < 0.05$ was considered significant.

RESULTS

[^{68}Ga]-DOTATATE PET/CT had a lesion-based detection rate of 98.6% (CI 96.5% to 99.5%), identifying 285 of 289 lesions (mean SUV 56.0 ± 62.1) compared to our defined imaging comparator. Significantly more lesions were identified on [^{68}Ga]-DOTATATE PET/CT compared to all other used functional imaging modalities and CT/MRI (two-sided $p < 0.01$ for each imaging modality compared to [^{68}Ga]-DOTATATE PET/CT;

corresponding cross tables in Supplemental Figure 1). Lesion-based findings on [⁶⁸Ga]-DOTATATE PET/CT compared to all other used functional imaging modalities and CT/MRI are summarized and outlined in Tables 2 and 3 as well as in Figure 1. Metastatic lesions were found in the mediastinum, lungs, liver, abdomen/pelvis, and bones. Those in the mediastinum, abdomen, or pelvis were located in lymphatic nodes. Three bone lesions, which were positive on [¹⁸F]-FDA and [¹⁸F]-FDG PET/CT, and one lung lesion, which was positive on [¹⁸F]-FDG PET/CT and anatomical imaging, were not identified by [⁶⁸Ga]-DOTATATE PET/CT. A lesion-based evaluation excluding the patient who only received [⁶⁸Ga]-DOTATATE, [¹⁸F]-FDG PET/CT, and CT/MRI did not lead to any statistical change.

Besides the 285 lesions confirmed by the defined imaging comparator, [⁶⁸Ga]-DOTATATE PET/CT detected 33 additional lesions: 8 in mediastinal lymphatic nodes, 10 in retroperitoneal and pelvic lymphatic nodes, and 15 bone lesions (mean SUV 8.2±6.4). All lesions were in the field of view of CT/MR. In the anatomical imaging studies CT/MRI, 8 lesions were reported, which were not positive on any functional imaging study. Two were retroperitoneal lymphatic nodes (1.5 centimeter (cm) and 1.6 cm), 4 were in the lungs (0.4 cm-0.8 cm), and two in the liver (0.7 cm and 0.8 cm). Three mediastinal lesions were only positive in [¹⁸F]-FDG PET/CT. Not a single lesion was only positive in either [¹⁸F]-FDOPA or [¹⁸F]-FDA PET/CT but not another functional or anatomic imaging test.

Per patient detection rates of [⁶⁸Ga]-DOTATATE, [¹⁸F]-FDG, [¹⁸F]-FDOPA, [¹⁸F]-FDA PET/CT and CT/MRI were 100% (17 out of 17 patients (17/17)), CI 81.6% to 100%, 100% (17/17), CI 81.6% to 100%, 87.5% (14/16), CI 64.0% to 96.5%, 81.3% (13/16), CI 57.0% to 93.4% and 100% (17/17), CI 81.6% to 100%, respectively.

The per region detection rate for [⁶⁸Ga]-DOTATATE was 100%, identifying 42 out of 42 regions (42/42), CI 91.6% to 100%, 97.6% for [¹⁸F]-FDG (41/42), CI 87.7% to 99.6%, 65.9% for [¹⁸F]-FDOPA (27/41), CI 50.6% to 78.4%, 58.4% for [¹⁸F]-FDA PET/CT (24/41), CI 43.4% to 72.2%, and 95.2% for CT/MRI (40/42), CI 84.2% to 98.7%.

A PET-imaging example comparing [⁶⁸Ga]-DOTATATE, [¹⁸F]-FDG, [¹⁸F]-FDOPA, and [¹⁸F]-FDA PET/CT is shown in [Figure 2](#).

DISCUSSION

In this study, we evaluated [⁶⁸Ga]-DOTATATE PET/CT in a cohort of patients with *SDHB*-related metastatic PHEOs/PGLs in comparison to [¹⁸F]-FDA, [¹⁸F]-FDOPA, [¹⁸F]-FDG PET/CT, and CT/MRI. The composite of both anatomical and all functional imaging tests was considered the imaging comparator.

[⁶⁸Ga]-DOTATATE PET/CT demonstrated a lesion-based detection rate of 98.6% (CI 96.5% to 99.5%), which was significantly superior to all other imaging modalities in this study, thus demonstrating the utility of this modality in localizing tumors in *SDHB*-related PHEO/PGL. We feel this modality will also be useful in determining the possible eligibility for PRRT in patients with *SDHB*-related PHEO/PGL.

Functional imaging agents are able to target PHEOs/PGLs through different mechanisms. [¹⁸F]-FDA as well as [¹²³I]-MIBG specifically target catecholamine synthesis, storage, and secretion pathways, and both enter the cell via the norepinephrine transporter (21, 22). In this study, [¹⁸F]-FDA had a low lesion-based detection rate of 51.9% (CI 46.1% to 57.7%), which might be explained by tumor dedifferentiation associated with loss of the norepinephrine transporter in these patients. This is supported by the reported [¹²³I]-MIBG negativity of more than 50% of patients in *SDHB* mutation-associated PHEOs/PGLs (12). Six of the patients in our study had undergone [¹²³I]-MIBG-scintigraphy with a very low lesion detection rate of 18.7% (CI 12.0% to 27.9%), but this result was most likely biased by the small patient cohort and the heavy disease burden of our patient population.

[¹⁸F]-FDOPA targets cells via the amino acid transporter system (23) and has demonstrated excellent results in patients with *SDHx* mutation-related head and neck PGLs (24). However, the lesion-based sensitivity of [¹⁸F]-FDOPA in *SDHB*-related PHEOs/PGLs outside the head and neck regions has been shown to be poor in a previous study (25). The detection rate in our study reached 61.4% (CI 55.6% to 66.9%).

[¹⁸F]-FDG is a sensitive but non-specific radiopharmaceutical that enters the cell via glucose transporters (GLUT) (26). Its accumulation is related to increased glucose metabolism as seen in many different types of tumors (26). In *SDHB*-related metastatic PGLs, its high sensitivity has been well documented (27-29). Higher standardized uptake values (SUV) compared to sporadic and other hereditary PHEO/PGL are also reported, accompanied by an upregulation of hexokinases 2 and 3 (30). Further, it is known that a mutation in the succinate dehydrogenase complex II subunit B can lead to a downregulation or loss of succinate dehydrogenase enzyme activity in the Krebs cycle, resulting in an upregulation of hypoxic angiogenic pathways via HIFs (6), which force tumor cells to shift from oxidative phosphorylation to aerobic glycolysis (Warburg effect) (31). Currently, [¹⁸F]-FDG PET/CT is recommended as the functional imaging technique of choice for patients with metastatic PHEOs/PGLs, including their follow-up and assessment of treatment-related responses (20, 32). In this study, we found a lesion-based detection rate of 85.8% (CI 81.3% to 89.4%) for [¹⁸F]-FDG PET/CT.

With a lesion-based detection rate of 98.6% (CI 96.5% to 99.5%), [⁶⁸Ga]-DOTATATE PET/CT was significantly superior to all other functional imaging modalities in this study. [⁶⁸Ga]-DOTATATE, which is known to have an approximately 10-fold higher affinity for SSTR2 than [⁶⁸Ga]-DOTATOC (which also has high affinity to SSTR5) and an approximately 100-fold higher affinity for SSTR2 than [¹¹¹In]-DTPA-octreotide (14), has already shown excellent results in the imaging of SSTR2 expressing gastroenteropancreatic NETs (33), and PHEOs/PGLs are also known to overexpress predominantly SSTR2 (13). A recent study also demonstrated an increased expression of SSTR2A and SSTR3 in PHEOs/PGLs with *SDH* deficiency (16), which also supports the approach of SSTR imaging and treatment in these tumors. Until now, there have only been a few small and heterogeneous studies and case reports on imaging of PHEOs/PGLs with DOTA-analogues. These have shown high sensitivities of [⁶⁸Ga]-DOTATATE and [⁶⁸Ga]-DOTATOC PET/CT, approaching or reaching 100% (17, 34).

Besides its diagnostic value, [^{68}Ga]-DOTATATE PET/CT can be used to determine which patients may benefit from PRRT, which would be a desirable new treatment option for these patients (7, 8). While PRRT has not been specifically evaluated in *SDHB*-related PHEOs/PGLs yet, it has already been shown to lead to longer progression-free survival, mainly in gastroenteropancreatic NETs (18) but also in other metastatic NETs, including PHEOs/PGLs (35). Unfortunately, PRRT is not approved by the United States Food and Drug Administration at present. In the meanwhile, the high sensitivity of [^{68}Ga]-DOTATATE PET/CT in *SDHB*-related metastatic PHEO/PGL suggests that these patients can be treated with cold SSTR analogs, including sandostatin LAR, lanreotide, or others. Although this approach has not yet been evaluated in PHEOs/PGLs, results using lanreotide in gastroenteropancreatic NETs (36) and individual reports of octreotide treatment in patients with head and neck PGLs support this approach (37, 38). This could also be extremely useful for patients in whom the location or extension of a PHEO/PGL lesion(s) (especially skull base) cannot be accessed by any surgical approach.

The phenomenon of additional lesions appearing with [^{68}Ga]-DOTA-analogues PET/CT that were not seen by other imaging studies has been reported before (15, 17). Since histologic proof of these lesions in our study was not possible, these lesions have to be discussed as false positive lesions. On the other hand, there are also studies that have reported histological confirmation of SSTR-positive tumor tissue in such cases, which led to a treatment change in up to 60% of patients (39).

Last, the high detection rate of [^{68}Ga]-DOTATATE PET/CT in these patients also suggests that the high malignant potential and presumed dedifferentiation of metastatic PHEOs/PGLs in *SDHB* mutations apparently do not lead to a significant loss of SSTR expression. This is supported by the increased SSTR2A and SSTR3 expression, which was found in *SDH*-deficient tumors (16). Recently, SSTR expression with positive [^{68}Ga]-DOTATOC PET/CT was also shown in patients with undifferentiated Epstein-Barr virus-related nasopharyngeal cancer (40). This also indicates that a loss in tumor differentiation is not necessarily combined with a loss in SSTR expression.

In the current guidelines, which do not yet take PET imaging with [^{68}Ga]-DOTA-peptides into consideration, [^{18}F]-FDG is recommended as first-line functional imaging of *SDHB*-related PHEO/PGL (20). However, our results indicate that [^{68}Ga]-DOTATATE PET/CT may have an incremental diagnostic value in the detection of disease sites, which could have an impact on patient care. Therefore, we believe that future guidelines may modify the recommendations in favor of using [^{68}Ga]-DOTA-peptides, especially if confirming results from a larger number of patients, sporadic PHEO/PGL patients, and other PHEO/PGL genotypes are made available.

In clinical settings such as the evaluation of treatment response after systemic radionuclide therapy or chemotherapy, the use of [^{68}Ga]-DOTATATE PET/CT is still unclear and has to be evaluated. In clinical settings of doubtful CT/MRI results, [^{68}Ga]-DOTATATE might also be helpful, although potential false positive results could occur. The more specific functional imaging studies like [^{18}F]-FDOPA and [^{18}F]-FDA PET/CT seem to harbor a higher risk for false negative results. Last, [^{18}F]-FDOPA PET/CT and especially [^{18}F]-FDA

PET/CT are of limited availability, whereas for [⁶⁸Ga]-DOTATATE PET/CT, we believe broader clinical availability can be expected in the future.

Our study was subject to certain limitations, including the relatively small number of patients and possible bias related to our chosen reference test. Based on this imaging comparator, combined positive findings in functional and/or anatomical imaging studies on one hand cannot fully exclude false positive results (e.g., possible positive lesions in [⁶⁸Ga]-DOTATATE PET/CT, [¹⁸F]-FDG-PET/CT, and/or CT/MRI related to inflammation or possible positive lesions in [⁶⁸Ga]-DOTATATE PET/CT, [¹⁸F]-FDOPA PET/CT, and/or CT/MRI related to different neuroendocrine tumors). On the other hand, true positive findings, which only appear in one imaging modality, e.g. CT/MRI, would have been counted as false positive in our setting.

In conclusion, although [¹⁸F]-FDG PET/CT is currently recommended as the functional imaging technique of choice in *SDHB*-related PHEOs/PGLs and our study is subject to certain limitations, we believe that our results may indicate a preference for [⁶⁸Ga]-DOTATATE PET/CT in these patients, particularly in the detection of progressive metastatic disease, additional disease sites, and even early detection of metastatic disease. [⁶⁸Ga]-DOTATATE PET/CT can also be used to help determine the eligibility of patients for PRRT, a new and hopefully soon to be available treatment option. The utility of [⁶⁸Ga]-DOTATATE PET/CT in other genotypes, sporadic PHEO/PGL, or for treatment monitoring should be evaluated soon.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

We would like to acknowledge the technical assistance of Joan Nambuba and Robert A. Wesley in the production of this manuscript.

Financial support: This work was supported, in part, by the Intramural Research Program of the National Institutes of Health, *Eunice Kennedy Shriver* National Institute of Child Health and Human Development.

REFERENCES

1. DeLellis, RA. Pathology and genetics of tumours of endocrine organs. IARC Press; Lyon: 2004.
2. Timmers HJ, Kozupa A, Eisenhofer G, Raygada M, Adams KT, Solis D, et al. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. *J Clin Endocrinol Metab.* 2007; 92:779–86. [PubMed: 17200167]
3. Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, et al. High frequency of *SDHB* germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. *J Clin Endocrinol Metab.* 2006; 91:4505–9. [PubMed: 16912137]
4. Castro-Vega LJ, Buffet A, De Cubas AA, Cascon A, Menara M, Khalifa E, et al. Germline mutations in *FH* confer predisposition to malignant pheochromocytomas and paragangliomas. *Hum Mol Genet.* 2014; 23:2440–6. [PubMed: 24334767]
5. Burnichon N, Cascon A, Schiavi F, Morales NP, Comino-Mendez I, Abermil N, et al. *MAX* mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. *Clin Cancer Res.* 2012; 18:2828–37. [PubMed: 22452945]

6. Jochmanova I, Yang C, Zhuang Z, Pacak K. Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. *J Natl Cancer Inst.* 2013; 105:1270–83. [PubMed: 23940289]
7. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. *J Clin Endocrinol Metab.* 2007; 92:3822–8. [PubMed: 17652212]
8. Matro J, Giubellino A, Pacak K. Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors. *Horm Metab Res.* 2013; 45:147–53. [PubMed: 23322515]
9. Taieb D, Neumann H, Rubello D, Al-Nahhas A, Guillet B, Hindie E. Modern nuclear imaging for paragangliomas: beyond SPECT. *J Nucl Med.* 2012; 53:264–74. [PubMed: 22302963]
10. van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. *Clin Endocrinol (Oxf).* 2014; 80:487–501. [PubMed: 24118038]
11. Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. *Cancer.* 2008; 113:2020–8. [PubMed: 18780317]
12. Fonte JS, Robles JF, Chen CC, Reynolds J, Whatley M, Ling A, et al. False-negative (1)(2)(3)I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. *Endocr Relat Cancer.* 2012; 19:83–93. [PubMed: 22167067]
13. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. *Eur J Nucl Med.* 2001; 28:836–46. [PubMed: 11504080]
14. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. *Eur J Nucl Med.* 2000; 27:273–82. [PubMed: 10774879]
15. Maurice JB, Troke R, Win Z, Ramachandran R, Al-Nahhas A, Naji M, et al. A comparison of the performance of (6)(8)Ga-DOTATATE PET/CT and (1)(2)(3)I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. *Eur J Nucl Med Mol Imaging.* 2012; 39:1266–70. [PubMed: 22526961]
16. Elston MS, Meyer-Rochow GY, Conaglen HM, Clarkson A, Clifton-Bligh RJ, Conaglen JV, et al. Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas. *Hum Pathol.* 2015; 46:390–6. [PubMed: 25554089]
17. Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. *J Med Imaging Radiat Oncol.* 2012; 56:40–7. [PubMed: 22339744]
18. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. *J Clin Oncol.* 2008; 26:2124–30. [PubMed: 18445841]
19. Zovato S, Kumanova A, Dematte S, Sansovini M, Bodei L, Di Sarra D, et al. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL). *Horm Metab Res.* 2012; 44:411–4. [PubMed: 22566197]
20. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab.* 2014; 99:1915–42. [PubMed: 24893135]
21. Sisson JC, Wieland DM. Radiolabeled meta-iodobenzylguanidine: pharmacology and clinical studies. *Am J Physiol Imaging.* 1986; 1:96–103. [PubMed: 3330445]
22. Timmers HJ, Eisenhofer G, Carrasquillo JA, Chen CC, Whatley M, Ling A, et al. Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). *Clin Endocrinol (Oxf).* 2009; 71:11–7. [PubMed: 19138315]

23. Havekes B, King K, Lai EW, Romijn JA, Corssmit EP, Pacak K. New imaging approaches to pheochromocytomas and paragangliomas. *Clin Endocrinol (Oxf)*. 2010; 72:137–45. [PubMed: 19508681]
24. King KS, Chen CC, Alexopoulos DK, Whatley MA, Reynolds JC, Patronas N, et al. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. *J Clin Endocrinol Metab*. 2011; 96:2779–85. [PubMed: 21752889]
25. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. *J Clin Endocrinol Metab*. 2009; 94:4757–67. [PubMed: 19864450]
26. Belhocine T, Spaepen K, Dusart M, Castaigne C, Muylle K, Bourgeois P, et al. 18FDG PET in oncology: the best and the worst (Review). *Int J Oncol*. 2006; 28:1249–61. [PubMed: 16596242]
27. Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. *J Clin Oncol*. 2007; 25:2262–9. [PubMed: 17538171]
28. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. *J Natl Cancer Inst*. 2012; 104:700–8. [PubMed: 22517990]
29. Mann GN, Link JM, Pham P, Pickett CA, Byrd DR, Kinahan PE, et al. [11C]methoxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. *Ann Surg Oncol*. 2006; 13:187–97. [PubMed: 16418883]
30. van Berkel A, Rao JU, Kusters B, Demir T, Visser E, Mensenkamp AR, et al. Correlation Between In Vivo 18F-FDG PET and Immunohistochemical Markers of Glucose Uptake and Metabolism in Pheochromocytoma and Paraganglioma. *J Nucl Med*. 2014; 55:1253–9. [PubMed: 24925884]
31. Warburg O. On the origin of cancer cells. *Science*. 1956; 123:309–14. [PubMed: 13298683]
32. Taieb D, Timmers HJ, Hindie E, Guillet BA, Neumann HP, Walz MK, et al. EANM 2012 guidelines for radionuclide imaging of pheochromocytoma and paraganglioma. *Eur J Nucl Med Mol Imaging*. 2012; 39:1977–95. [PubMed: 22926712]
33. Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Wangler B, Uebleis C, et al. The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. *J Nucl Med*. 2012; 53:1686–92. [PubMed: 22984220]
34. Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, et al. A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma. *Eur J Nucl Med Mol Imaging*. 2013; 40:1800–8. [PubMed: 24072345]
35. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. *J Clin Oncol*. 2011; 29:2416–23. [PubMed: 21555692]
36. Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. *N Engl J Med*. 2014; 371:224–33. [PubMed: 25014687]
37. Elshafie O, Al Badaai Y, Alwahaibi K, Qureshi A, Hussein S, Al Azzri F, et al. Catecholamine-secreting carotid body paraganglioma: successful preoperative control of hypertension and clinical symptoms using high-dose long-acting octreotide. *Endocrinol Diabetes Metab Case Rep*. 2014; 2014:140051. [PubMed: 25136449]
38. Kau R, Arnold W. Somatostatin receptor scintigraphy and therapy of neuroendocrine (APUD) tumors of the head and neck. *Acta Otolaryngol*. 1996; 116:345–9. [PubMed: 8725546]
39. Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal

- management of patients with neuroendocrine tumors. *Ann Surg.* 2010; 252:850–6. [PubMed: 21037441]
40. Schartinger VH, Dudas J, Url C, Reinold S, Virgolini JJ, Kroiss A, et al. (68)Ga-DOTA (0)-Tyr (3)-octreotide positron emission tomography in nasopharyngeal carcinoma. *Eur J Nucl Med Mol Imaging.* 2015; 42:20–4. [PubMed: 25227762]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

TRANSLATIONAL RELEVANCE

Patients with succinate dehydrogenase subunit *B* (*SDHB*) mutation-related pheochromocytoma/paraganglioma (PHEO/PGL) are known to suffer from aggressive tumor behavior that has a very high likelihood of metastasis. This work focuses solely on the performance of [⁶⁸Ga]-DOTA(0)-Tyr(3)-octreotate ([⁶⁸Ga]-DOTATATE) PET/CT in patients with metastatic *SDHB*-related PHEOs/PGLs and demonstrates the superiority of [⁶⁸Ga]-DOTATATE PET/CT in the detection of metastatic lesions in these patients, compared to all other and currently recommended functional imaging modalities. Our results may suggest modifying the functional imaging algorithm for these patients, dependent on the clinical setting, which currently places [¹⁸F]-fluoro-2-deoxy-D-glucose ([¹⁸F]-FDG) PET/CT as the gold standard. Furthermore, our results indicate that peptide receptor radionuclide therapy or treatment with so-called “cold” somatostatin receptor analogs, long-awaited remedies, could be used as new and promising therapeutic options for patients with metastatic *SDHB*-related PHEOs/PGLs.




Figure 1. Identified lesions (positive columns) and missed lesions (negative columns) for CT/MRI, [18F]-FDG, [68Ga]-DOTATATE, [18F]-FDOPA, and [18F]-FDA PET/CT.




Figure 2. 24-year-old female patient with metastatic paraganglioma and *SDHB* mutation, first diagnosed with left carotid body tumor, lung and bone metastases in 2011. [^{68}Ga]-DOTATATE PET (A) demonstrated additional lung and bone lesions (arrows), compared to [^{18}F]-FDG PET (B) and [^{18}F]-FDOPA PET (C). [^{18}F]-FDA PET (D) and [^{123}I]-MIBG scintigraphy (not shown) were negative.

Table 1

Individual patient characteristics.

Pt. #	Sex	SDHB mutation	Age (d)	Age (s)	LOP	Hyper secretion	TTM	LOM	Treatment
1	m	c.725G>A, p.Arg242His	20	34	R skull	None	12	B	RT skull
2	f	c.688G>T, p.Arg230Cys	22	25	L carotid body	None	0	B, Lu, Me	Res primary
3	m	c.418G>T, p.Val140Phe	10	20	Aortic bifurcation	NE, NMN, DA	0	B, A/P	Res primary
4	m	c.689G>A, p.Arg230His	52	52	R para-adrenal	NE, NMN	0	B	RT skull Res primary
5	f	c.343G>T, p.Arg115X	32	43	Urinary bladder	NE, NMN	3	B, Lu, A/P	Res primary, CVD
6	f	c.689G>A, p.Arg230His	28	50	L carotid body	None	20	Lu, Li	Res primary, CVD
7	f	c.136C>T, p.Arg46X	19	24	R glomus jugulare	None	0	B, Ne	Res primary, RT skull
8	m	c.200+33G>A, p.Glu228Glyfsx27	47	59	L para-adrenal	DA, MTT	3	Me, Ne, A/P	Res. primary
9	m	c.136C>T, p.Arg46X	45	46	urinary bladder	NE, NMN,	0	Lu, B	Res primary
10	m	c.136C>T, p.Arg46X	25	37	R mediastinal	None	0	Lu	Res primary, CVD
11	m	c.72+1G>T	54	60	R para-adrenal	NE, NMN	0	Lu, Me, A/P, B	Res primary , MIBG
12	f	Exon 1 deletion	49	55	Aortic bifurcation	NE, NMN, DA, MTT	0	Ne, Me, A/P	Res primary, MIBG
13	m	c.330_331del, p.Leu111SerfsX7	10	23	L adrenal	NE, NMN	0	B, Lu, Ne, A/P, Li	Res primary
14	m	c.268C>T, p.Arg90X	11	26	R adrenal	None	8	B, Lu, Ne	Res primary, MIBG
15	m	Exon 1 deletion	34	41	R para-adrenal	NMN, DA, MTT	5	Me, B	Res primary
16	m	c.137G>A, p.Arg46Gln	19	36	L pelvis	NE, NMN, DA, MTT	13	B, Lu, Ne, A/P	Res primary, MIBG, CVD
17	f	c.541-2A>G, splice site mutation	36	54	L carotid body	NE, NMN, DA, MTT	8	B	Res primary

Abbreviations: Age (d), age at diagnosis; age (s), age at study; A/P, abdomen/pelvis; B, bones; CVD, chemotherapy with CVD; DA, dopamine; f, female, L, left; LOM, location of metastases; LOP, location of primary; Lu, lungs; m, male; Me, mediastinum, MIBG, ¹³¹I-MIBG treatment; Mtt, methoxytyramine, Ne, neck; NE, norepinephrine; NMN, normetanephrine; no, number; Pat., patient; R, right; Res, surgical resection; RT, radionuclide therapy; TTM, time to metastases (years).

Table 2

Number of identified lesions in [⁶⁸Ga]-DOTATATE, [¹⁸F]-FDA-, [¹⁸F]-FDOPA-, [¹⁸F]-FDG-PET/CT, and CT/MRI compared to lesions identified by the imaging comparator.

Lesions	[⁶⁸ Ga]-DOTATATE	[¹⁸ F]-FDG	[¹⁸ F]-FDOPA	[¹⁸ F]-FDA	CT/MRI
All compartments	285/289	248/289	175/285	148/285	245/289
Mediastinum	65/65	57/65	39/65	39/65	55/65
Lungs	62/63	45/63	45/63	18/63	62/63
Abdomen	43/43	40/43	31/43	19/43	33/43
Liver	5/5	3/5	4/5	0/5	5/5
Bone	95/98	91/98	41/94	57/94	82/98

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3

Detection rate (%) and 95% CI (%) for [⁶⁸Ga]-DOTATATE, [¹⁸F]-FDA-, [¹⁸F]-FDOPA-, [¹⁸F]-FDG-PET/CT, and CT/MRI.

Detection rate	[⁶⁸ Ga]-DOTATATE	[¹⁸ F]-FDG	[¹⁸ F]-FDOPA	[¹⁸ F]-FDA	CT/MRI
All compartments	98.6 (96.5 to 99.5)	85.8 (81.3 to 89.4)	61.4 (55.6 to 66.9)	51.9 (46.1 to 57.7)	84.8 (80.0 to 88.5)
Mediastinum	100 (94.4 to 100)	87.7 (77.6 to 93.6)	60.0 (47.9 to 71.0)	60.0 (47.9 to 71.0)	84.6 (73.9 to 91.4)
Lungs	98.4 (92.5 to 99.7)	71.4 (59.3 to 81.1)	71.4 (59.3 to 81.1)	28.6 (18.9 to 40.7)	98.4 (91.5 to 99.7)
Abdomen	100 (91.8 to 100)	93.0 (81.4 to 97.6)	72.1 (57.3 to 83.3)	44.2 (30.4 to 58.9)	76.7 (62.3 to 88.7)
Liver	100 (56.5 to 100)	60.0 (23.1 to 88.2)	80.0 (37.6 to 96.4)	0% (0.0 to 43.5)	100 (56.5 to 100)
Bone	96.9 (91.4 to 99.0)	92.9 (86.0 to 96.5)	43.6 (34.0 to 53.7)	60.6 (50.5 to 69.9)	83.7 (75.1 to 89.7)